{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:45:22Z","timestamp":1792028722801,"version":"4.4.0"},"reference-count":155,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T00:00:00Z","timestamp":1565395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Dopamine transporter (DAT) single-photon emission tomography (SPECT) with (123)Ioflupane is a widely used diagnostic tool for patients with suspected parkinsonian syndromes, as it assists with differentiating between Parkinson\u2019s disease (PD) or atypical parkinsonisms and conditions without a presynaptic dopaminergic deficit such as essential tremor, vascular and drug-induced parkinsonisms. Recent evidence supports its utility as in vivo proof of degenerative parkinsonisms, and DAT imaging has been proposed as a potential surrogate marker for dopaminergic nigrostriatal neurons. However, the interpretation of DAT-SPECT imaging may be challenged by several factors including the loss of DAT receptor density with age and the effect of certain drugs on dopamine uptake. Furthermore, a clear, direct relationship between nigral loss and DAT decrease has been controversial so far. Striatal DAT uptake could reflect nigral neuronal loss once the loss exceeds 50%. Indeed, reduction of DAT binding seems to be already present in the prodromal stage of PD, suggesting both an early synaptic dysfunction and the activation of compensatory changes to delay the onset of symptoms. Despite a weak correlation with PD severity and progression, quantitative measurements of DAT binding at baseline could be used to predict the emergence of late-disease motor fluctuations and dyskinesias. This review addresses the possibilities and limitations of DAT-SPECT in PD and, focusing specifically on regulatory changes of DAT in surviving DA neurons, we investigate its role in diagnosis and its prognostic value for motor complications as disease progresses.<\/jats:p>","DOI":"10.3390\/cells8080872","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T06:38:02Z","timestamp":1565591882000},"page":"872","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Molecular Imaging of the Dopamine Transporter"],"prefix":"10.3390","volume":"8","author":[{"given":"Giovanni","family":"Palermo","sequence":"first","affiliation":[{"name":"Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, 56,126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ceravolo","sequence":"additional","affiliation":[{"name":"Unit of Neurology, Department of Clinical and Experimental Medicine, University of Pisa, 56,126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","article-title":"Neuropathology of Parkinson disease","volume":"46","author":"Dickson","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tins.2007.03.009","article-title":"Multiple hit hypothesis for dopamine neuron loss in Parkinson\u2019s disease","volume":"30","author":"Sulzer","year":"2007","journal-title":"Trends Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1002\/mds.10578","article-title":"Dopamine transporter: Basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism","volume":"18","author":"Uhl","year":"2003","journal-title":"Mov. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.baga.2016.02.001","article-title":"Striatal dopamine neurotransmission: Regulation of release and uptake","volume":"6","author":"Sulzer","year":"2016","journal-title":"Basal Ganglia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2018.11.004","article-title":"Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters","volume":"122","author":"Mulvihill","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO;2-V","article-title":"Correlation of Parkinsons disease severity and duration with [123I]FP-CIT SPECT striatal uptake","volume":"15","author":"Benamer","year":"2000","journal-title":"Mov. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00702-006-0518-2","article-title":"Striatal FP-CIT uptake differs in the subtypes of early Parkinson\u2019s disease","volume":"114","author":"Spiegel","year":"2007","journal-title":"J. Neural Transm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1468-1331.2009.02898.x","article-title":"Differences in nigro-striatal impairment in clinical variants of early Parkinson\u2019s disease: Evidence from a FP-CIT SPECT study","volume":"17","author":"Rossi","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/jnnp.62.2.133","article-title":"[123I]FP-SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson\u2019s disease","volume":"62","author":"Booij","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_10","first-page":"584","article-title":"Binding of [99mTc- ]TRODAT-1 to dopamine transporters in patients with Parkinson\u2019s disease and in healthy volunteers","volume":"41","author":"Mozley","year":"2000","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1212\/WNL.57.11.2089","article-title":"[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson\u2019s disease progression","volume":"57","author":"Marek","year":"2001","journal-title":"Neurology"},{"key":"ref_12","first-page":"1703","article-title":"Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson\u2019s disease subjects","volume":"38","author":"Kim","year":"1997","journal-title":"J. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.112.105379","article-title":"Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: An update","volume":"54","author":"Tatsch","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40035-017-0076-6","article-title":"Imaging biomarkers in Parkinson\u2019s disease and Parkinsonian syndromes: Current and emerging concepts","volume":"6","author":"Saeed","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/jnnp-2012-304436","article-title":"Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes","volume":"84","author":"Bajaj","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/mds.10092","article-title":"[123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson\u2019s disease","volume":"17","author":"Gerschlager","year":"2002","journal-title":"Mov. Disord."},{"key":"ref_17","first-page":"1688","article-title":"123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism","volume":"45","author":"Lorberboym","year":"2004","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.parkreldis.2012.03.017","article-title":"The relationship between cerebral vascular disease and parkinsonism: The VADO study","volume":"18","author":"Antonini","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/jnnp-2012-302618","article-title":"Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson\u2019s disease","volume":"84","author":"Carrillo","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/mds.10575","article-title":"DAT imaging in drug-induced and psychogenic parkinsonism","volume":"18","author":"Tolosa","year":"2003","journal-title":"Mov. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.20748","article-title":"[123I]-FP\/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson\u2019s disease","volume":"21","author":"Lorberboym","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.schres.2012.06.003","article-title":"[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism","volume":"139","author":"Tinazzi","year":"2012","journal-title":"Schizophr. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/mds.22259","article-title":"Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study","volume":"23","author":"Ceravolo","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/mds.22771","article-title":"Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors","volume":"24","author":"Novellino","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mds.22986","article-title":"Mixed tremors with integrity of nigrostriatal system: A clinical and DAT-SPECT follow-up study","volume":"25","author":"Arabia","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1468-1331.2012.03875.x","article-title":"I123-FP-CIT single-photon emission tomography in patients with long-standing mixed tremor","volume":"20","author":"Renard","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/jnnp-2014-310256","article-title":"What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies","volume":"87","author":"Erro","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00415-011-6076-z","article-title":"The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: A critical assessment of 125 cases","volume":"258","author":"Liepe","year":"2011","journal-title":"J. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/01.mnm.0000243374.11260.5b","article-title":"Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging","volume":"27","author":"Marshall","year":"2006","journal-title":"Nucl. Med. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/WNN.0000000000000107","article-title":"Cognition in patients with a clinical diagnosis of Parkinson disease and scans without evidence of dopaminergic deficit (SWEDD): 2-year follow-up","volume":"29","author":"Martin","year":"2016","journal-title":"Cogn. Behav. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/jon.12391","article-title":"Cerebral glucose metabolism and dopaminergic function in patients with corticobasal syndrome","volume":"27","author":"Mille","year":"2017","journal-title":"J. Neuroimaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1212\/WNL.0000000000003512","article-title":"Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB","volume":"88","author":"Thomas","year":"2017","journal-title":"Neurology"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cilia, R., Rossi, C., Frosini, D., Volterrani, D., Siri, C., Pagni, C., Benti, R., Pezzoli, G., Bonuccelli, U., and Antonini, A. (2011). Dopamine transporter SPECT imaging in corticobasal syndrome. PLos ONE, 6.","DOI":"10.1371\/journal.pone.0018301"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.parkreldis.2013.01.013","article-title":"Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study","volume":"19","author":"Ceravolo","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3233\/JPD-150625","article-title":"Progressive dopamine transporter binding loss in autopsy-confirmed corticobasal degeneration","volume":"5","author":"Pirker","year":"2015","journal-title":"J. Parkinsons Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s00259-016-3312-x","article-title":"[(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies","volume":"43","author":"Booij","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/01.mnm.0000202858.45522.df","article-title":"123I-FP-CIT in progressive supranuclear palsy and in Parkinson\u2019s disease: A SPECTsemiquantitative study","volume":"27","author":"Filippi","year":"2006","journal-title":"Nucl. Med. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/mds.24000","article-title":"Dopamine transporter imaging in autopsy-confirmed Parkinson\u2019s disease and multiple system atrophy","volume":"27","author":"Kovacs","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/jon.12530","article-title":"I-123 DaTscan SPECT Brain Imaging in Parkinsonian Syndromes: Utility of the Putamen-to-Caudate Ratio","volume":"28","author":"Matesan","year":"2018","journal-title":"J. Neuroimaging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00415-011-6163-1","article-title":"Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson\u2019s disease","volume":"259","author":"Kahraman","year":"2012","journal-title":"J. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12149-014-0878-x","article-title":"Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson\u2019s disease and atypical parkinsonian syndromes using DaTSCAN (R) SPECT","volume":"28","author":"Davidsson","year":"2014","journal-title":"Ann. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/B978-0-444-53485-9.00024-6","article-title":"Imaging of genetic and degenerative disorders primarily causing Parkinsonism","volume":"135","author":"Brooks","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1471-4159.2006.03719.x","article-title":"The dopamine transporter proteome","volume":"97","author":"Torres","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0014-2999(93)90390-4","article-title":"Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents","volume":"250","author":"Ikawa","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mds.870120204","article-title":"The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys","volume":"12","author":"Rioux","year":"1997","journal-title":"Mov. Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410430504","article-title":"Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions","volume":"43","author":"Murer","year":"1998","journal-title":"Ann. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0006-8993(94)91872-4","article-title":"The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat\u2013an autoradiographic study","volume":"640","author":"Gnanalingham","year":"1994","journal-title":"Brain Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J","article-title":"Effect of treatment with Levodopa-Carbidopa or L-Selegiline on striatal dopamine transporter SPECT imaging with I [123]Beta-CIT","volume":"14","author":"Innis","year":"1999","journal-title":"Mov. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1212\/WNL.56.11.1559","article-title":"Influence of L-Dopa and pramipexole on striatal dopamine transporter in early PD","volume":"56","author":"Guttman","year":"2001","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y","article-title":"The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson\u2019s disease","volume":"14","author":"Ahlskog","year":"1999","journal-title":"Mov. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (2002). Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA, 287, 1653\u20131661.","DOI":"10.1001\/jama.287.13.1653"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/mol.106.027763","article-title":"D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism","volume":"7","author":"Bolan","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.nbd.2014.12.007","article-title":"Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake","volume":"74","author":"Moratalla","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1471-4159.2011.07357.x","article-title":"SKF-83566, a D1 dopamine receptor antagonist, inhibits the dopamine transporter","volume":"118","author":"Stouffer","year":"2011","journal-title":"J. Neurochem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/WNF.0000000000000198","article-title":"Striatal dopamine transporter modulation after rotigotine: Results from a pilot single-photon emission computed tomography study in a group of early stage Parkinson disease patients","volume":"40","author":"Rossi","year":"2017","journal-title":"Clin. Neuropharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Ikeda, K., Ebina, J., Kawabe, K., and Iwasaki, Y. (2019). Dopamine Transporter Imaging in Parkinson Disease: Progressive Changes and Therapeutic Modification after Anti-parkinsonian Medications. Intern. Med., Epub ahead of print.","DOI":"10.2169\/internalmedicine.2489-18"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.npp.1300036","article-title":"Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration","volume":"28","author":"Kugaya","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/YIC.0b013e32835ebcd7","article-title":"No changes in striatal dopamine transporter in antidepressant-treated patients with major depression","volume":"28","author":"Wu","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/jnnp.2006.111666","article-title":"Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer\u2019s disease from dementia with Lewy bodies","volume":"78","author":"Taylor","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10072-018-3253-1","article-title":"Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson\u2019s disease","volume":"39","author":"Gigante","year":"2018","journal-title":"Neurol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.pnpbp.2007.08.018","article-title":"Decreased dopamine transporter availability in male smokers\u2014A dual isotope SPECT study","volume":"32","author":"Yang","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00213-019-05196-1","article-title":"Tobacco smoking and dopaminergic function in humans: A meta-analysis of molecular imaging studies","volume":"236","author":"Ashok","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eurpsy.2019.03.003","article-title":"Effects of stimulant drug use on the dopaminergic system: A systematic review and meta-analysis of in vivo neuroimaging studies","volume":"59","author":"Proebstl","year":"2019","journal-title":"Eur. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridinelesioned macaque model of Parkinson\u2019s disease","volume":"21","author":"Bezard","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1093\/brain\/aws211","article-title":"Neuropathological correlates of dopaminergic imaging in Alzheimer\u2019s disease and Lewy body dementias","volume":"135","author":"Colloby","year":"2012","journal-title":"Brain"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/mds.25975","article-title":"Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts","volume":"29","author":"Kraemmer","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ana.23798","article-title":"Validation of nigrostriatal positron emission tomography measures: Critical limits","volume":"73","author":"Karimi","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1212\/WNL.0000000000003810","article-title":"Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease","volume":"88","author":"Saari","year":"2017","journal-title":"Neurology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/01.wnr.0000227984.84927.a7","article-title":"Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson\u2019s disease","volume":"17","author":"Sasaki","year":"2006","journal-title":"Neuroreport"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2013.02.012","article-title":"Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson\u2019s disease using neuromelanin-sensitive MR imaging","volume":"29","author":"Ohtsuka","year":"2013","journal-title":"Neurosci. Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00234-013-1171-8","article-title":"3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the sub stantia nigra pars compacta for diagnosis of Parkinson\u2019s disease","volume":"55","author":"Ogisu","year":"2013","journal-title":"Neuroradiology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.parkreldis.2014.04.005","article-title":"Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging","volume":"20","author":"Ohtsuka","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/ene.12613","article-title":"Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson\u2019s disease patients","volume":"22","author":"Reimao","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1148\/radiol.2016160662","article-title":"In vivo assessment of brainstem depigmentation in Parkinson disease: Potential as a severity marker for multicenter studies","volume":"283","author":"Schwarz","year":"2017","journal-title":"Radiology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/ene.13573","article-title":"Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson\u2019s disease","volume":"25","author":"Prasad","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mdc3.12590","article-title":"Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism","volume":"22","author":"Pavese","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/mds.26182","article-title":"Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson\u2019s disease","volume":"30","author":"Reimao","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jocn.2010.08.043","article-title":"Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson\u2019s disease","volume":"18","author":"Kashihara","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3174\/ajnr.A3567","article-title":"Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)Imetaiodobenzylguanidine scintigraphy","volume":"34","author":"Miyoshi","year":"2013","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00234-013-1199-9","article-title":"Correlation between pathology and neuromelanin MR imaging in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"55","author":"Kitao","year":"2013","journal-title":"Neuroradiology"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Bastida, A., Lao-Kaim, N.P., Roussakis, A.A., Searle, G.E., Xing, Y., Gunn, R.N., Schwarz, S.T., Barker, R.A., Auer, D.P., and Piccini, P. (2019). Relationship between neuromelanin and dopamine terminals within the Parkinson\u2019s nigrostriatal system. Brain, Epub ahead of print.","DOI":"10.1093\/brain\/awz120"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00234-016-1644-7","article-title":"Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism","volume":"58","author":"Kuya","year":"2016","journal-title":"Neuroradiology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fnagi.2016.00196","article-title":"Neuromelanin imaging and dopaminergic loss in Parkinson\u2019s disease","volume":"8","author":"Isaias","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/mds.25015","article-title":"Magnetic resonance imaging of the substantia nigra in Parkinson\u2019s disease","volume":"27","author":"Lehericy","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1148\/radiol.14131448","article-title":"MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease","volume":"271","author":"Cosottini","year":"2014","journal-title":"Radiology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1212\/WNL.0b013e31829e6fd2","article-title":"Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7 T MRI","volume":"81","author":"Blazejewska","year":"2013","journal-title":"Neurology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26968","article-title":"The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward","volume":"32","author":"Lehericy","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneurol.2016.152","article-title":"Advances in markers of prodromal Parkinson disease","volume":"12","author":"Postuma","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1474-4422(10)70216-7","article-title":"Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study","volume":"9","author":"Iranzo","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1212\/WNL.0000000000003838","article-title":"Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases","volume":"88","author":"Li","year":"2017","journal-title":"Neurology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ana.25026","article-title":"Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic REM sleep behavior disorder","volume":"82","author":"Iranzo","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/mds.26255","article-title":"Nigral anatomy and striatal denervation in genetic parkinsonism: A family report","volume":"30","author":"Ceravolo","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ana.24646","article-title":"Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder","volume":"79","author":"Seppi","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.26584","article-title":"Loss of nigral hyperintensity on 3 Tesla MRI of parkinsonism: Comparison with (123) I-FP-CIT SPECT","volume":"31","author":"Bae","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00702-016-1529-2","article-title":"Nigral involvement in atypical parkinsonisms: Evidence from a pilot study with ultra-high field MRI","volume":"123","author":"Frosini","year":"2016","journal-title":"J. Neural Transm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.parkreldis.2017.08.002","article-title":"Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder","volume":"43","author":"Frosini","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4","article-title":"In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson\u2019s disease","volume":"47","author":"Lee","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/mds.26620","article-title":"Early synaptic dysfunction in Parkinson\u2019s disease: Insights from animal models","volume":"31","author":"Schirinzi","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Dijkstra, A.A., Ingrassia, A., de Menezes, R.X., van Kesteren, R.E., Rozemuller, A.J., Heutink, P., and van de Berg, W.D. (2015). Evidence for Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson\u2019s Disease. PLos ONE, 10.","DOI":"10.1371\/journal.pone.0128651"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.51.2_Suppl_2.S2","article-title":"Biochemical aspects of Parkinson\u2019s disease","volume":"51","author":"Hornykiewicz","year":"1998","journal-title":"Neurology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2174\/1871527314666150317225659","article-title":"Lewy bodies: A spectator or salient killer?","volume":"14","author":"Monoranu","year":"2015","journal-title":"Cns Neurol. Disord. Drug Targets"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Parkinson\u2019s Progression Marker Initiative. Longitudinal change of clinical and biological measures in early Parkinson\u2019s disease: Parkinson\u2019s Progression Markers Initiative cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fnins.2018.00080","article-title":"Mechanisms of \u03b1-Synuclein Induced Synaptopathy in Parkinson\u2019s Disease","volume":"12","author":"Bridi","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1038\/s41598-017-06724-9","article-title":"Early synaptic dysfunction induced by \u03b1-synuclein in a rat model of Parkinson\u2019s disease","volume":"7","author":"Phan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.20226","article-title":"Parkinsonian signs and substantia nigra neuron density in decendents elders without PD","volume":"56","author":"Ross","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The Emerging Evidence of the Parkinson Pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/brain\/awq059","article-title":"Relationships between age and late progression of Parkinson\u2019s disease: A clinico-pathological study","volume":"133","author":"Kempster","year":"2010","journal-title":"Brain"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1471-4159.1992.tb09766.x","article-title":"Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of idiopathic Parkinson\u2019s disease","volume":"58","author":"Kish","year":"1992","journal-title":"J. Neurochem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.neurobiolaging.2007.09.009","article-title":"Aging effects on the dopamine transporter expression and compensatory mechanisms","volume":"30","author":"Abreu","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s12149-014-0882-1","article-title":"Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson\u2019s disease","volume":"28","author":"Lee","year":"2014","journal-title":"Ann. Nucl. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neurobiolaging.2015.01.016","article-title":"Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson\u2019s disease","volume":"36","author":"Kaasinen","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.parkreldis.2011.11.025","article-title":"The aging striatal dopamine function","volume":"18","author":"Darbin","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1212\/WNL.0000000000002102","article-title":"Parkinson disease and incidental Lewy body disease: Just a question of time?","volume":"85","author":"Iacono","year":"2015","journal-title":"Neurology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"S656","DOI":"10.1002\/mds.22672","article-title":"When does Parkinson\u2019s disease begin?","volume":"24","author":"Gaig","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.410410213","article-title":"Dopaminergic function in familial Parkinson\u2019s disease: A clinical and [18F]dopa positron emission tomography study","volume":"41","author":"Piccini","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/1531-8249(199905)45:5<577::AID-ANA5>3.0.CO;2-O","article-title":"The role of inheritance in sporadic Parkinson\u2019s disease: Evidence from a longitudinal study of dopaminergic function in twins","volume":"45","author":"Piccini","year":"1999","journal-title":"Ann. Neurol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/brain\/awh607","article-title":"PET inLRRK2 mutations: Comparison to sporadic Parkinson\u2019s disease and evidence for presymptomatic compensation","volume":"128","author":"Adams","year":"2005","journal-title":"Brain"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","article-title":"Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction","volume":"117","author":"Beach","year":"2009","journal-title":"Acta Neuropathol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/archneur.63.4.584","article-title":"Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra","volume":"63","author":"Greffard","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0166-2236(90)90112-N","article-title":"Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications","volume":"13","author":"Zigmond","year":"1990","journal-title":"Trends Neurosci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tins.2003.12.006","article-title":"How does Parkinson\u2019s disease begin? The role of compensatory mechanisms","volume":"27","author":"Obeso","year":"2004","journal-title":"Trends Neurosci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jnnp.2008.157370","article-title":"The role of DAT-SPECT in movement disorders","volume":"81","author":"Kagi","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0166-2236(03)00038-9","article-title":"Presymptomatic compensation in Parkinson\u2019s disease is not dopamine-mediated","volume":"26","author":"Bezard","year":"2003","journal-title":"Trends Neurosci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/WNL.0b013e318198e0e9","article-title":"Mechanisms compensating for dopamine loss in early Parkinson disease","volume":"72","author":"Brotchie","year":"2009","journal-title":"Neurology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.expneurol.2017.10.002","article-title":"Compensatory mechanisms in Parkinson\u2019s disease: Circuits adaptations and role in disease modification","volume":"298","author":"Blesa","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s007020050004","article-title":"Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations","volume":"107","author":"Pal","year":"2000","journal-title":"J. Neural Transm."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.65","article-title":"Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson\u2019s disease: PET evidence of increased dopamine turnover","volume":"49","author":"Lu","year":"2001","journal-title":"Ann. Neurol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: Implications for dyskinesias","volume":"127","author":"Sossi","year":"2004","journal-title":"Brain"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/brain\/awh102","article-title":"Presynaptic mechanisms of motor fluctuations in Parkinson\u2019s disease: A probabilistic model","volume":"127","author":"Schulzer","year":"2004","journal-title":"Brain"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ana.21204","article-title":"Dopamine transporter relation to dopamine turnover in Parkinson\u2019s disease: A positron emission tomography study","volume":"62","author":"Sossi","year":"2007","journal-title":"Ann. Neurol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mds.26046","article-title":"Central pharmacokinetics of levodopa: Lessons from imaging studies","volume":"30","author":"Stoessl","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1212\/01.wnl.0000338631.73211.56","article-title":"PET demonstrates reduced dopamine transporter expression in PD with dyskinesias","volume":"72","author":"Troiano","year":"2009","journal-title":"Neurology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1212\/WNL.0000000000000385","article-title":"Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease","volume":"82","author":"Hong","year":"2014","journal-title":"Neurology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1212\/WNL.0000000000002286","article-title":"Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications","volume":"86","author":"Mende","year":"2016","journal-title":"Neurology"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Tomas, D., Stanic, D., Chua, H.K., White, K., Boon, W.C., and Horne, M. (2016). Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson\u2019s Disease. PLos ONE, 11.","DOI":"10.1371\/journal.pone.0153424"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00259-017-3844-8","article-title":"Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson\u2019s disease","volume":"45","author":"Yoo","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1093\/brain\/awp209","article-title":"Longitudinal progression of sporadic Parkinson\u2019s disease: A multitracer positron emission tomography study","volume":"132","author":"Nandhagopal","year":"2009","journal-title":"Brain"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.parkreldis.2018.05.008","article-title":"Putaminal dopamine depletion in de novo Parkinson\u2019s disease predicts future development of wearing-off","volume":"53","author":"Chung","year":"2018","journal-title":"Parkinsonism Relatdisord."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/WNF.0b013e3181b52792","article-title":"Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: A pharmacological and SPECT study","volume":"32","author":"Linazasoro","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jns.2018.05.006","article-title":"Can early dopamine transporter imaging serve as a predictor of Parkinson\u2019s disease progression and late motor complications?","volume":"390","author":"Djaldetti","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: Filling the bench-to-bedside gap","volume":"9","author":"Calabresi","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/mds.25157","article-title":"Dopamine transporter imaging is associated with long-term outcomes in Parkinson\u2019s disease","volume":"27","author":"Ravina","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.parkreldis.2012.05.022","article-title":"Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson\u2019s disease patients","volume":"18","author":"Erro","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.parkreldis.2014.04.006","article-title":"Caudate dopaminergic denervation and visual hallucinations: Evidence from a 123I-FP-CIT SPECT study","volume":"20","author":"Kiferle","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.parkreldis.2015.02.015","article-title":"Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson\u2019s disease patients","volume":"21","author":"Santangelo","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.parkreldis.2018.02.047","article-title":"Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson\u2019s disease: An analysis of the PPMI cohort","volume":"51","author":"Kim","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.autneu.2018.09.005","article-title":"Association of autonomic symptoms with presynaptic striatal dopamine depletion in drug-naive Parkinson\u2019s disease: An analysis of the PPMI data","volume":"216","author":"Kim","year":"2019","journal-title":"Auton. Neurosci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1474-4422(17)30328-9","article-title":"Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson\u2019s disease: A longitudinal cohort study and validation","volume":"16","author":"Latourelle","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.27183","article-title":"11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson\u2019s: A longitudinal study","volume":"33","author":"Li","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neurobiolaging.2015.11.009","article-title":"Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson\u2019s disease","volume":"38","author":"Lee","year":"2016","journal-title":"Neurobiol. Aging"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/8\/872\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:10:15Z","timestamp":1760188215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/8\/872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,10]]},"references-count":155,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["cells8080872"],"URL":"https:\/\/doi.org\/10.3390\/cells8080872","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,10]]}}}